Kodiak Sciences reported that both Zenkuda and tabirafusp alfa tedromer met the one-year visual-acuity noninferiority endpoint versus aflibercept in the approximately 690-patient Phase 3 DAYBREAK study. Fifty-four percent of Zenkuda-treated patients reached a 24-week…
Link Cell Therapies expanded its previously announced $60 million Series A to $90 million. The additional $30 million brings strategic investors including Bristol Myers Squibb and Kyowa Kirin alongside JJDC, Samsara BioCapital, Sheatree Capital…
Link Cell Therapies appointed Jie D’Elia chief executive officer and director, Friedrich Graf Finckenstein chief medical officer and co-founder Brian Slingerland executive chair as LNK001 entered Phase 1 and the Series A expanded to…
Link Cell Therapies initiated clinical dosing of LNK001, an autologous logic-gated CAR-T therapy that requires coexpression of CAIX and ENPP3, in a Phase 1 clear-cell renal-cell-carcinoma study at MD Anderson. The design directly addresses…
AstraZeneca agreed to invest $2.0 billion in newly issued Summit Therapeutics convertible preferred equity and to test Summit’s ivonescimab with AstraZeneca antibody-drug conjugates. The initial collaboration pairs ivonescimab, a PD-1/VEGF bispecific originally engineered by…
Mirum reported that brelovitug met the Phase 3 AZURE-1 primary endpoint in treatment-naive chronic hepatitis delta virus infection. At week 24, 56% of patients receiving 300 mg weekly and 45% receiving 900 mg every…
Merck acquired exclusive worldwide development, manufacturing and commercialization rights to SPR2015 from Shanghai-based SciBrunch Therapeutics. Merck will pay $400 million upfront; total potential consideration, including the upfront, is $2.13 billion. The transaction has closed….
Adicet reported Phase 1 data for prulacabtagene leucel, an allogeneic gamma-delta anti-CD20 CAR-T therapy, in systemic lupus erythematosus with or without lupus nephritis. At 12 months, 54% of evaluable patients achieved DORIS remission and…
The week’s most important signal was not a new platform claim but five-year, maintenance-free disease control after a single cilta-cel infusion in early-line relapsed or refractory multiple myeloma — and the broader pattern held…
Daiichi Sankyo and Merck voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer after FDA discussions concluded that the supporting data, including Phase 2 IDeate-Lung01, did not…
